Table 4.
Clinicopathologic characteristics of patients according to sarcosine metabolism type
| Parameter | Total N =721 (%) | High sarcosine type n = 36 (%) | Intermediate sarcosine type n = 21 (%) | Low sarcosine type n = 219 (%) | Null type n = 445 (%) | P -value |
|---|---|---|---|---|---|---|
| Age (years) |
|
|
|
|
|
0.200 |
| ≤50 |
428 (59.4) |
26 (72.2) |
13 (61.9) |
120 (54.8) |
269 (60.4) |
|
| >50 |
293 (40.6) |
10 (27.8) |
8 (38.1) |
99 (45.2) |
176 (39.6) |
|
| Histologic grade |
|
|
|
|
|
0.351 |
| I/II |
485 (67.3) |
29 (80.6) |
13 (61.9) |
147 (67.1) |
296 (66.5) |
|
| III |
236 (32.7) |
7 (19.4) |
8 (38.1) |
72 (32.9) |
149 (33.5) |
|
| Tumor stage |
|
|
|
|
|
0.082 |
| T1 |
355 (49.2) |
12 (33.3) |
10 (47.6) |
120 (54.8) |
213 (47.9) |
|
| T2/T3 |
366 (50.8) |
24 (66.7) |
11 (52.4) |
99 (45.2) |
232 (52.1) |
|
| Nodal metastasis |
|
|
|
|
|
0.799 |
| Absent |
427 (59.2) |
22 (61.1) |
14 (66.7) |
125 (57.1) |
266 (59.8) |
|
| Present |
294 (40.8) |
14 (38.9) |
7 (33.3) |
94 (42.9) |
179 (40.2) |
|
| Estrogen receptor status |
|
|
|
|
|
0.049 |
| Negative |
259 (35.9) |
9 (25.0) |
3 (14.3) |
75 (34.2) |
172 (38.7) |
|
| Positive |
462 (64.1) |
27 (75.0) |
18 (85.7) |
144 (65.8) |
273 (61.3) |
|
| Progesterone receptor status |
|
|
|
|
|
0.011 |
| Negative |
347 (48.1) |
13 (36.1) |
4 (19.0) |
102 (46.6) |
228 (51.2) |
|
| Positive |
374 (51.9) |
23 (63.9) |
17 (81.0) |
117 (53.4) |
217 (48.8) |
|
| HER-2 status |
|
|
|
|
|
0.072 |
| Negative |
565 (78.4) |
24 (66.7) |
17 (81.0) |
163 (74.4) |
361 (81.1) |
|
| Positive |
156 (21.6) |
12 (33.3) |
4 (19.0) |
56 (25.6) |
84 (18.9) |
|
| Ki-67 LI (%) |
|
|
|
|
|
0.007 |
| ≤14 |
409 (56.7) |
21 (58.3) |
17 (81.0) |
138 (63.0) |
233 (52.4) |
|
| >14 |
312 (43.3) |
15 (41.7) |
4 (19.0) |
81 (37.0) |
212 (47.6) |
|
| Tumor recurrence |
63 (8.7) |
8 (22.2) |
1 (4.8) |
15 (6.8) |
39 (8.8) |
0.022 |
| No. of patient deaths | 61 (8.5) | 5 (13.9) | 1 (4.8) | 20 (9.1) | 35 (7.9) | 0.558 |
Bold number represents p<0.05.
TNBC, triple negative breast cancer.